R Mistry1, A Walker1, D Kim1, E Ofo1. 1. St George's University Hospitals NHS Foundation Trust, Tooting, London, UK.
Abstract
INTRODUCTION: Head and neck carcinoma of unknown primary represents 1-5% of all head and neck cancers and presents a diagnostic and therapeutic dilemma. In approximately 40% of cases, a primary tumour location remains unknown despite investigation. With advancements in our understanding of the role of high-risk human papilloma virus in head and neck cancer, transoral robotic surgery presents an option for diagnosis and therapy. MATERIALS AND METHODS: This is a retrospective case series from a single centre. Case notes were reviewed for 28 patients who had transoral robotic surgery for head and neck carcinoma of unknown primary between May 2015 and July 2019. RESULTS: Transoral robotic surgery identified an oropharyngeal primary tumour in 19 of 28 (67.8%) patients. All oropharyngeal primaries were p16 positive. The base of tongue identification rate was 63.2%. Median length of inpatient stay postoperatively was 1.0 day. Normal oral intake resumed within 48 hours in 96% (27/28) of patients. Three patients (10.3%) suffered minor postoperative bleeds that were all managed conservatively. DISCUSSION: The base of tongue primary identification rate (63.2%) in this series is consistent with that previously reported (43-63%; 95% confidence interval). Primary tumour identification rate if a patient is p16 positive is 86.3% (19/22), with 100% of these being oropharyngeal. We suggest future investigation into p16 status as a means of stratifying patients with head and neck carcinoma of unknown primary for transoral robotic surgery. CONCLUSION: Transoral robotic base of tongue mucosectomy (or lingual tonsillectomy) is a promising technique that offers a high yield of positive identification for the primary tumour. It is well tolerated with minimal associated morbidity. Our findings are comparable with those in the current literature.
INTRODUCTION: Head and neck carcinoma of unknown primary represents 1-5% of all head and neck cancers and presents a diagnostic and therapeutic dilemma. In approximately 40% of cases, a primary tumour location remains unknown despite investigation. With advancements in our understanding of the role of high-risk human papilloma virus in head and neck cancer, transoral robotic surgery presents an option for diagnosis and therapy. MATERIALS AND METHODS: This is a retrospective case series from a single centre. Case notes were reviewed for 28 patients who had transoral robotic surgery for head and neck carcinoma of unknown primary between May 2015 and July 2019. RESULTS: Transoral robotic surgery identified an oropharyngeal primary tumour in 19 of 28 (67.8%) patients. All oropharyngeal primaries were p16 positive. The base of tongue identification rate was 63.2%. Median length of inpatient stay postoperatively was 1.0 day. Normal oral intake resumed within 48 hours in 96% (27/28) of patients. Three patients (10.3%) suffered minor postoperative bleeds that were all managed conservatively. DISCUSSION: The base of tongue primary identification rate (63.2%) in this series is consistent with that previously reported (43-63%; 95% confidence interval). Primary tumour identification rate if a patient is p16 positive is 86.3% (19/22), with 100% of these being oropharyngeal. We suggest future investigation into p16 status as a means of stratifying patients with head and neck carcinoma of unknown primary for transoral robotic surgery. CONCLUSION: Transoral robotic base of tongue mucosectomy (or lingual tonsillectomy) is a promising technique that offers a high yield of positive identification for the primary tumour. It is well tolerated with minimal associated morbidity. Our findings are comparable with those in the current literature.
Entities:
Keywords:
Carcinoma of the unknown primary; Human papilloma virus; Lingual tonsillectomy; Tongue-base mucosectomy; Transoral robotic surgery; head and neck cancer
Authors: Hanna Mellin Dahlstrand; David Lindquist; Linda Björnestål; Ann Ohlsson; Tina Dalianis; Eva Munck-Wikland; Göran Elmberger Journal: Anticancer Res Date: 2005 Nov-Dec Impact factor: 2.480
Authors: S C Winter; E Ofo; D Meikle; P Silva; L Fraser; J O'Hara; D Kim; M Robinson; V Paleri Journal: Clin Otolaryngol Date: 2017-03-26 Impact factor: 2.597
Authors: Vikas Mehta; Paul Johnson; Andrew Tassler; Seungwon Kim; Robert L Ferris; Melonie Nance; Jonas T Johnson; Umamaheswar Duvvuri Journal: Laryngoscope Date: 2012-11-14 Impact factor: 3.325
Authors: Kyle M Hatten; Bert W O'Malley; Andres M Bur; Mihir R Patel; Christopher H Rassekh; Jason G Newman; Steven B Cannady; Ara A Chalian; Benjamin L Hodnett; Alexander Lin; John N Lukens; Roger B Cohen; Joshua M Bauml; Kathleen T Montone; Virginia A Livolsi; Gregory S Weinstein Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-03-01 Impact factor: 6.223
Authors: R Michael Baskin; Brian J Boyce; Robert Amdur; William M Mendenhall; Kathryn Hitchcock; Natalie Silver; Peter T Dziegielewski Journal: Cancer Manag Res Date: 2018-04-20 Impact factor: 3.989
Authors: Rhona A Beynon; Samantha Lang; Sarah Schimansky; Christopher M Penfold; Andrea Waylen; Steven J Thomas; Michael Pawlita; Tim Waterboer; Richard M Martin; Margaret May; Andy R Ness Journal: Int J Cancer Date: 2018-04-23 Impact factor: 7.396